2015
DOI: 10.1016/j.jmii.2013.08.006
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: A prospective cohort study

Abstract: In our study, nasogastric tube placement and hospitalization within the previous 3 months were significantly associated with the acquisition of ESBL-producing pathogens in community-onset UTI.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

8
18
1
7

Year Published

2015
2015
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 36 publications
(34 citation statements)
references
References 38 publications
8
18
1
7
Order By: Relevance
“…The prevalence of ESBL-PE among Enterobacteriaceae responsible for community-onset invasive infections among children in our hospital in France was still lower than that observed in adults 5,26,35 but similar to or even higher than the rates observed in recent European pediatric studies. 10,32 Regarding the marked spread of these resistant isolates in fecal carriage among children without any underlying disease 6,8,9 and the high rate of ESBL-PE community-onset infections in non-European countries, reaching nearly 10%, 36,38 pediatricians should be prepared for a continual increase in prevalence of ESBL-PE infection.…”
Section: Discussionsupporting
confidence: 74%
See 1 more Smart Citation
“…The prevalence of ESBL-PE among Enterobacteriaceae responsible for community-onset invasive infections among children in our hospital in France was still lower than that observed in adults 5,26,35 but similar to or even higher than the rates observed in recent European pediatric studies. 10,32 Regarding the marked spread of these resistant isolates in fecal carriage among children without any underlying disease 6,8,9 and the high rate of ESBL-PE community-onset infections in non-European countries, reaching nearly 10%, 36,38 pediatricians should be prepared for a continual increase in prevalence of ESBL-PE infection.…”
Section: Discussionsupporting
confidence: 74%
“…The prevalence of reported risk factors was studied: gender, 5,20,23,30,34,38 age, 1,11,20,23,26,28,31,32,50 country of birth, 25 travel outside metropolitan France, 23,32 underlying chronic disease 23,24,26,28,32,34,36,38,50 and urinary tract disease, 5,10,20,23,25,27,30,39,40 previous hospitalization. 10,11,20,21,24,29,31,32,35,39,43,5052 (excluding hospitalization within the last 3 months before current infection), previous antibiotic therapy, 1,20,21,25–33,3638,43,50 known ESBL carriage; 21 factors included in the definition of healthcare-associated infections were excluded. Their distribution between patients with community- and healthcare-associated invasive infections was compared.…”
Section: Methodsmentioning
confidence: 99%
“…However, only a few studies have examined what predispose patients with no discernible HCA risk factors to develop ESBL-EC UTIs and how these patients differ clinically from those with non-ESBL-EC UTIs. Most previous studies have focused on bloodstream infections, which represent the most serious form of E. coli infections, and combined CA and HCA infections in their analyses without analyzing them separately (5,6). Because HCA infections often resemble hospital-acquired infections and tend to have more severe symptoms (7)(8)(9)(10), the impact of ESBL production on treatment outcomes might be overestimated in CA infections, which might potentially lead to overtreatment for less serious infections.…”
mentioning
confidence: 99%
“…Por esta razón, la Sociedad Estadounidense de Enfermedades Infecciosas (IDSA, por sus siglas en inglés) listó a las enterobacterias productoras de BLEE ademas del Acinetobacter baumannii, especies de Aspergillus, Enterococcus faecium resistente a vancomicina, Pseudomonas aeruginosa y al Staphylococcus aureus meticilino-resistente, como microorganismos resistentes que requieren con prioridad, nuevos tratamientos 2,13,14 .…”
Section: Discussionunclassified